<DOC>
	<DOCNO>NCT00004166</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug amifostine may protect normal cell side effect chemotherapy . PURPOSE : Randomized phase III trial study effectiveness amifostine treat patient ovarian epithelial cancer receive chemotherapy .</brief_summary>
	<brief_title>Amifostine Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine patient ovarian epithelial cancer receive chemotherapy significantly few neurologic event treat amifostine . II . Compare amifostine v chemoprotection term overall incidence neuropathy , incidence neutropenia , infection , myelosuppressive event ( e.g. , leukopenia , anemia , thrombocytopenia ) , length hospital stay due infection , quality life patient population . OUTLINE : This randomize , parallel , control , double blind study . Patients randomize one two treatment arm . Arm I : Patients receive amifostine IV 10 minute , 30 minute prior chemotherapy . Arm II : Patients receive placebo IV 10 minute , 30 minute prior chemotherapy . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Quality life assess prior course 1 , 4 , 8 , every 3 month 1 year . Patients follow monthly 6 month . PROJECTED ACCRUAL : A total 60 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , surgically stag ovarian epithelial cancer Planned treatment paclitaxel/carboplatinum chemotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 3 mg/dL SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine great 2 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Other : At least 24 hour since prior antihypertensive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>quality life</keyword>
</DOC>